METTL3 and familial pancreatic carcinoma: In this study, we provided evidence for a role of NUCB1 in regulating proliferation and the anti-tumor effects of gemcitabine in pancreatic cancer cells, and proposed a mechanism whereby METTL3 controls NUCB1 expression, which then modulates ATF activity and subsequently controls the UPR (Figure 7).